Kirby · Current issues in molecular biology 2024 · in vitro simulation study · n=?

AG1 ® Induces a Favorable Impact on Gut Microbial Structure and Functionality in the Simulator of Human Intestinal Microbial Ecosystem ® Model.

Cited 3 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

In vitro laboratory study using a simulated gut model (SHIME) without human clinical intervention

PubMed 38248338 · doi:10.3390/cimb46010036 · record verified 2026-08-26

What was done

An in vitro study evaluated the multi-ingredient nutritional supplement AG1 using the Simulator of Human Intestinal Microbial Ecosystem (SHIME) model. The supplement underwent simulated digestion, absorption, and a 48-hour colonic fermentation using fecal inocula from healthy human donors. Gut microbiota community structure (alpha diversity, beta diversity, specific taxa) and functional capacity (metabolic pathways) were analyzed using shallow shotgun whole-genome sequencing.

What was found

The abstract reports no significant change in alpha diversity. Significant main effects of treatment and donor, as well as a treatment-by-donor interaction, were reported for structural heterogeneity (beta diversity), linked to differential enrichment of 8 bacterial taxa. Functional heterogeneity also shifted significantly, associated with enrichment in 20 Gene Ontology metabolic pathways. The abstract provides no exact numerical values, effect sizes, or specific taxonomic names.

Why it matters

This study provides benchtop laboratory evidence that AG1 can alter bacterial representation and metabolic potential in an artificial gut environment, serving as hypothesis-generating data for future in vivo trials.

Limits

The study is entirely in vitro; simulated gut models cannot replicate systemic human physiology, host mucosal interactions, immune responses, or clinical outcomes. The abstract omits the number of fecal donors, baseline donor characteristics, exact quantitative metrics, and specific identities of the enriched taxa and pathways.

Cited by